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Human b-defensins play a pivotal role in the innate
immune response. Although expressed by and
acting at epithelial surfaces, little is known about
their specific interaction with epithelial structures.
Here, we identify the transmembrane protein CD98
as a cell surface receptor involved in the internaliza-
tion of human b-defensin 3 (hBD3) in human epithelial
A549 cells. CD98 and hBD3 extensively colocalize on
the basolateral domain of A549. While verifying their
direct binding by fluorescence resonance energy
transfer and surface plasmon resonance, we map-
ped the interaction to CD98 residues 304–414, i.e.
to the region known to interact with the proteins of in-
testinal bacteria during colonic invasion. Treatment
of A549 cells with hBD3 dramatically reduces CD98
expression and conversely, knockdown of CD98
expression impairs hBD3 cell surface binding and
internalization. Competition for bacterial binding to
CD98 and downregulation of CD98 expression may
represent novel mechanisms for the antibacterial
activity of hBD3.
INTRODUCTION
Human b-defensins (hBDs) are cationic peptides that play a
pivotal role in the innate immune response. They display strong
chemotactic activity toward immune cells, activating and ampli-
fying the adaptive immune response. Moreover, hBDs exert anti-
microbial activity against a wide spectrum of bacteria and
viruses, through binding to the plasma membrane of pathogens
and subsequent pore formation (Dhople et al., 2006; Semple and
Dorin, 2012; Yamaguchi and Ouchi, 2012; Sudheendra et al.,
2014). To date, more than 6 hBDs have been identified but the
best characterized are hBD1–4 (Jarczak et al., 2013). Their anti-Chemistry & Biology 22, 217microbial activities have been extensively studied and much
effort was made to design more potent analogs. Another aspect
that has been investigated is maintenance of antimicrobial activ-
ity in the presence of high salt concentration, such as observed in
the respiratory epithelia of patients with cystic fibrosis (Smith
et al., 1996). While hBD1, 2, and 4 are inactivated by high salt
conditions, hBD3 is salt resistant, and hence more attractive
for therapeutic use (Ganz, 2003; Sass et al., 2010; Harder
et al., 2001). The combination of high potency and salt resistance
was also investigated previously by us with hDB1/hBD3 chi-
meras to enhance the potency and breadth of their antibacterial
activity (Scudiero et al., 2010, 2013).
All hBDs contain six highly conserved cysteine (Cys) residues,
which dictate a rigid conformation stabilized by three disulfide
bridges. Most hBDs are amphipathic, with a net positive charge
that confers on them features similar to cell-penetrating pep-
tides, short positively charged amphipathic peptides that
penetrate biological membranes (Zorko and Langel, 2005). In
particular, hBD3 is the protein product of the human gene
DEFB103 and belongs to the naturally occurring supercharged
human proteins (NSHPs), which can penetrate human cells (Cro-
nican et al., 2011; Thompson et al., 2012) and, with a net charge
of +11, has the highest charge to mass ratio in NSHPs. All hBDs
are secreted by epithelia, and their expression is upregulated in
the course of infection and inflammation in order to act as a
chemical barrier against pathogens (Semple and Dorin, 2012).
However, although epithelia represent the natural site of action
of these peptides, little is known about the interaction of hBDs
with human epithelial cells.
We previously showed that hBD1, hBD3, and hBD1/hBD3 chi-
meras are not toxic to human epithelial cell lines and that they are
internalized into the cytoplasm via an active endocytic mecha-
nism (Scudiero et al., 2010). Consistent with our findings, hBD3
fused to the mCherry fluorophore was also shown to be able to
penetrate human cells (Cronican et al., 2011). We have now
analyzed in greater detail the interaction of hBD3 with the human
pulmonary epithelial cell line A549. In particular, we addressed
the question of whether hBD3 internalization is mediated by spe-
cific receptors on epithelial cells, as described for the receptors–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 217
Figure 1. Synthesis of Biotin-2X-hBD3
(A) Structure of the Biotin-2X-hBD3 peptide (Biotin-2X has a side chain to the cyclic part of the molecule of two more 5-carbon chains that bind to the N-terminal
glycine of hBD3) used to identify hBD3 membrane protein interactors. hBD3 has a net positive charge of +11.
(B) Biotin-2X-hBD3 was identified by positive ESI LC-MS. Analytical RP-HPLC (left panel) was performed with a reverse-phase C18 column using as solvent
system H2O/0.1 TFA and CH3CN/0.1% TFA, and a linear gradient 5%–50% of CH3CN/0.1% TFA over 17 min, at a flow rate of 1 ml/min. The ESI + full MS
spectrum (right panel, mass range: 150–2,000 Da) shows the Biotin-2X-hBD3 multicharged ions in the range of 8.76–9.33 min, which corresponds to the peptide
retention time. The theoretical mass of the peptide is 5614 Da. See also Figure S1.expressed on immune cells, the binding of which also triggers
chemotaxis (Soruri et al., 2007; Ro¨hrl et al., 2010). In this context,
it is noteworthy that hBD3 has been implicated in the modulation
of melanocortin receptors (Beaumont et al., 2012; Nix et al.,
2013). Our analysis identifies 4F2/CD98 as an hBD3-specific
membrane receptor and shows that it is internalized by means
of recycling endosomes.
RESULTS
Internalization and Trafficking of Biotin-Labeled hBD3
Synthesis of Biotin-Labeled hBD3
We used biotin as label. Biotin was incorporated at the N termi-
nus of the peptide using standard solid-phase peptide synthesis
(Figure 1). Unless otherwise specified, we used the fully reduced,
purified peptide, since the antibacterial activity of hBD3 does not
differ between the oxidized (hereafter referred to as hBD3ox)
and reduced forms (Scudiero et al., 2013), as also shown in
Figure S1.
Biotin-Labeled hBD3 Maintains Antibacterial Activity
against Escherichia coli
To ensure that biotin did not alter the antibacterial properties of
hBD3, we tested Biotin-2X-hBD3 against Escherichia coli in
comparison with reduced and oxidized unlabeled hBD3 using
two concentrations of peptide (2.5 and 12.5 mM), and four con-
centrations of NaCl (0.0, 50, 100, and 200 mM) (Figure S1). The
minimum inhibitory concentration ranged between 12.5 and218 Chemistry & Biology 22, 217–228, February 19, 2015 ª2015 Else25.0 mM for all the peptides, thereby confirming that biotinylation
does not impair the antibacterial activity of hBD3.
hBD3 Localizes at the Basolateral Plasma Membrane of
Polarized Epithelial A549 Cells from which It Is
Internalized through Recycling Endosomes
To explore the localization of hBD3 on the plasmamembrane, we
incubated Biotin-2X-hBD3 with live epithelial cells cultured on a
transwell filter, both apically and basolaterally, for 20 min at 4C
(pulse), then with streptavidin-Cy3 conjugated, and lastly with
E-cadherin, a marker of the basolateral plasma membrane
(Miranda et al., 2003). As shown in Figure 2A, Biotin-2X-hBD3
extensively colocalized with E-cadherin at the basolateral
domain of the A549 plasma membrane.
We (Scudiero et al., 2013) and others (Mburu et al., 2011) pre-
viously reported that hBD3 is able to enter mammalian cells via
an active endocytic mechanism. To investigate the mechanism
of hBD3 entry, we specifically labeled recycling endosomes us-
ing a transferrin-Alexa488 conjugate. A549 cells were incubated
with the peptide and transferrin-Alexa488 for 20 min at 4C
(pulse) and then at 37C for different chase times. Biotin-2X-
hBD3 extensively colocalizes with transferrin up to 30 min of
chase after 0 min, 15 min, and 30 min of chase (Figure 2B), indi-
cating that internalization is largely driven through recycling en-
dosomes. Internalization via early endosomes and localization
to the lysosomal pathway was ruled out by lack of colocalization
of hBD3 with either the early endosome marker EE1 or with
the endo/lysosomal marker LAMP-1 after 0 min, 15 min, andvier Ltd All rights reserved
Figure 2. Biotin-2X-hBD3 Specifically Distributes on the Basolateral Domain of the Plasma Membrane
(A) A549 cells, grown on a filter for 72 hr, were incubated with the peptide (10 mM) for 20min at 4C (pulse), washed and labeled with streptavidin-Cy3 and amarker
of the basolateral cell membrane (E-cadherin). Scale bars, 10 mm. Images represent single 1-mm-thick optical slices. Biotin-2X-hBD3 is red, E-cadherin green,
and nuclei blue; colocalization appears orange-yellow in the overlay image. Results are from three independent experiments, withR100 cells per experiment.
(B) Biotin-2X-hBD3 colocalizes with transferrin into recycling endosomes. A549 cells were incubated with the peptide (10 mM) and with a marker of recycling
endosomes (transferrin-Alexa488 conjugated) for 20 min at 4C (pulse), washed and incubated at 37C for different chase times. Scale bars, 10 mm. Images
represent single 1-mm-thick optical slices. Biotin-hBD3 is red, transferrin-Alexa488 is green, nuclei are blue; colocalizing regions appear orange-yellow in the
overlay image. Three independent experiments were performed, and images were acquired from at least 100 cells per experiment.30 min of chase throughout the kinetics of the endocytic assays
(data not shown).
Functional Proteomics Identifies 4F2/CD98 as a
Putative Interactor of hBD3
To identify hBD3 interactors on the plasma membrane of A549
cells, we applied a functional proteomic approach using Biotin-
2X-hBD3 as a bait to capture interacting membrane proteins
(Figure S2). Biotin-2X-hBD3was incubated with A549 cells as re-
ported in Experimental Procedures. Cells were then subjected to
subcellular fractionation to isolate membrane components. The
efficiency of subcellular fractionation was evaluated by Western
blotting (see Figure S3A). The Biotin-2X-hBD3 crosslinked com-
plexes were purified by affinity chromatography using streptavi-
din magnetic beads (see also Figure S2). Protein extract from
cells incubated with Biotin-2X alone was used as negative con-Chemistry & Biology 22, 217trol. Then, the protein partners were eluted and decrosslinked,
as described elsewhere (Sutherland et al., 2008; Klockenbusch
and Kast, 2010) (see Figure S3B), fractionated by SDS-PAGE,
stained, and submitted to mass spectrometry for protein
identification.
Among the 19 proteins identified in this study, we focused on
4F2/CD98, which is a membrane protein involved in L-type
amino acid transport, in integrin-mediated cell adhesion, and
notably, in inflammation and in the immune response (Nguyen
et al., 2011; Nguyen and Merlin, 2012). We observed the CD98
protein in cells treated with Biotin-2X-hBD3 but not in those
treated with Biotin-2X alone (Figure 3A, lanes 1 and 2). Western
blot analysis of the proteins obtained from Biotin-2X-hBD3
crosslinking yielded positive staining with an anti-CD98 anti-
body, whereas no significant staining was observed for the con-
trol samples from the control biotin crosslinking (Figure 3B).–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 219
Figure 3. Functional Proteomics Identifies
4F2/CD98 as a Putative Interactor of hBD3
(A) Separation of Biotin-2X-hBD3-interacting
membrane proteins (lane 1) in A549 cells. The gel
was stained with Coomassie brilliant blue and
bands were excised and subjected to LC-MS/MS
analysis. Peptide-protein complexes from cells
incubated with Biotin-2X only and eluted from
streptavidin beadswas used as control (lane 2). The
CD98 protein, identified by LC-MS/MS analysis, is
boxed.Lane1shows themolecularweightmarkers.
(B) Western blot analysis of Biotin-2X-hBD3 com-
plexes isolated by affinity purification with anti-
CD98 and anti-hBD3. Lane 1: membrane proteins
crosslinked to the Biotin-2X-hBD3 peptide, used
as input for the affinity chromatography experi-
ment. Lane 2: Biotin-2X-hBD3 complexes eluted
from streptavidin beads and decrosslinked.
Lane 3: peptide-protein complexes from cells
incubated with Biotin-2X without hBD3, and eluted
from streptavidin beads used as control. See also
Figures S2 and S3.Confocal Microscopy Confirms the hBD3-CD98
Interaction on the Cell Surface
Cell surface interaction of CD98 with Biotin-2X-hBD3 was
confirmed by confocal microscopy (Figure 4A). A549 cells incu-
bated with the peptide for 20 min at 4C and then immuno-
stained with CD98, Biotin-2X-hBD3, and CD98 extensively
colocalized at the basolateral membrane (Figure 4A). Confocal
microscopy of cells fixed and coimmunostained with CD98 and
Biotin-2X-hBD3 showed about 11% of fluorescence resonance
energy transfer (FRET) efficiency measured by the acceptor
photobleaching technique (Figure 4B), a value indicating that
the two partners are close enough to allow energy transfer.
Indeed, acceptor bleaching (Biotin-2X-hBD3 labeled with strep-
tavidin Cy5) resulted in a significant increase of donor (CD98
Cy3) emission in cells labeled with hBD3 and CD98. We found
FRET when we bleached selected plasma membrane regions
of interest. The percentage of FRET efficiency is shown in
Figure 4C.
To verify the specificity of hBD3 binding to CD98, we per-
formed a competition binding assay (see Figure 5). First, we
used a titration curve to determine the optimal peptide concen-
tration that resulted in a linear correspondence between concen-
tration and fluorescence signal (Figure 5A), and selected 3 mM
Biotin-2X-hBD3. Then, we performed the competition binding
assay in two distinct setups: (1) preincubation of Biotin-2X-
hBD3 for 20 min at 4C followed by hBD3 for a further 20 min
at 4C (Figure 5B[b,c]); and (2) preincubation of hBD3 for
20 min at 4C followed by Biotin-2X-hBD3 for a further 20 min
at 4C (Figure 5B[d,e]). In cells pretreated with unlabeled
hBD3, there was a notable decrease of Biotin-2X-hBD3 binding;
conversely, fluorescence was not affected when the incubation
of cold hBD3 was performed after exposure to labeled Biotin-
2X-hBD3. This suggests that once hBD3 binds to cells, the sub-
sequent incubation with Biotin-2X-hBD3 is not able to displace
the binding of the peptide from the plasma membrane. These
data indicate that hBD3 binding to the cell membrane is specific
and occurs with a good affinity, which is consistent with the value
of the dissociation constant (KD) (see Table 1).220 Chemistry & Biology 22, 217–228, February 19, 2015 ª2015 ElseTrafficking of hBD3 and CD98 after Internalization
We then monitored the fate of CD98 after binding to hBD3 (Fig-
ure 6A). A549 cells were incubated with the peptide for 20 min at
4C, then at 37C for different chase times, and immunostained
with CD98. Starting from the plasma membrane, where the two
partners colocalize, we found that Biotin-2X-hBD3 colocalized
with CD98 in endocytic vesicles at different chase times (Fig-
ure 6A), which is in agreement with the observation that hBD3
is internalized by means of recycling endosomes and accumu-
lates with transferrin (Figure 2B).
Silencing of CD98 Prevents Binding and Internalization
of hBD3
We tested the effect of silencing on the synthesis of CD98 by
specific small interfering RNA (siRNA) interference. The higher
efficiency of the CD98-specific siRNA molecule versus a
nonspecific scrambled control was confirmed by Western blot
(Figure S4A) and by confocal microscopy (Figure S4B). A com-
parison of the Biotin-2X-hBD3 signal in CD98-knockdown
A549 cells versus nontreated cells (Figure 6B) revealed that, in
the silenced cells, hBD3 was neither able to bind the plasma
membrane nor to enter the cells. Therefore, consistent with the
images shown in Figure 4A, these results support the concept
that hBD3 binding on the cell membrane is effectively dependent
on CD98 expression.
Treatment of A549 Cells with hBD3 Leads to Reduced
CD98 Expression
In a complementary experiment, we observed that treatment of
A549 cells with Biotin-2X-hBD3 resulted in a decrease in the
amount of CD98 24 hr post treatment (Figure S5). This is similar
to the HIV coreceptor CXCR4, the internalization and downregu-
lation of which are modulated by both hBD2 and hBD3
(Quin˜ones-Mateu et al., 2003; Feng et al., 2006).
Characterization of the CD98-hBD3 Interaction by
Surface Plasmon Resonance
The molecular interaction between CD98 and hBD3 was further
studied by surface plasmon resonance (SPR) (see also Figures
S6A and S6B) (Jason-Moller et al., 2006). To identify thevier Ltd All rights reserved
Figure 4. Biotin-2X-hBD3 Colocalizes and Directly Interacts with CD98
(A) A549 cells were grown on filters for 72 hr, incubated with the peptide (10 mM) for 20 min at 4C (pulse), then washed and immunostained with CD98. Biotin-2X-
hBD3 colocalized with CD98 at 0 min. Scale bars, 10 mm. Images represent single 1-mm-thick optical slices. Biotin-2X-hBD3 is red, CD-98 is green, nuclei labeled
with DAPI are in blue; colocalization appears orange-yellow in the overlay image. Three independent experiments were performed, and images were acquired
fromR100 cells per experiment.
(B) hBD3/CD98 direct interaction. FRET was measured with the acceptor photobleaching technique as described in Experimental Procedures. The image shows
the signal of biotinylated hBD3 (red) and CD98 (green) before (a, b, c prebleach) and after (d, e, f postbleach) photobleaching. The selected regions of interest for
bleaching are indicated.
(C) Energy transfer efficiency was measured in cells immunostained for Biotin-2X-hBD3 and CD98 and is expressed in % as the mean of three independent
experiments. Error bars: ± SD. *Highly significant difference (p < 0.001). See also Figures S4 and S5.interacting regions of CD98, the three protein sequences shown
in Figure 7A were selected, hereafter referred to as GST-CD98,
GST-CD98cut, and CD98-6His. All proteins were covalently
immobilized on the appropriate chip (see Experimental Proce-
dures). Subsequently, both reduced and oxidized hBD3 solu-
tions, at various concentrations, were allowed to flow on all the
immobilized CD98 molecules. To verify the occurrence of bind-
ing, reduced hBD3 was covalently immobilized on a CM5 sensor
chip. Then, a series of concentrations of all three CD98 se-
quences was allowed to flow on the immobilized hBD3.
Except for the GST-hBD3 pair, in which no interaction was de-
tected, a ligand-analyte molecular interaction was detected in all
measurements, in full agreement with the other data reported in
this study. The SPR data were fitted using a two-state model to
calculate the kinetic and equilibrium dissociation constants of
the hBD3-CD98 complexes. KD values are reported in Table 1.
These data confirm the occurrence of high-affinity binding be-
tween hBD3 and CD98 and in addition provide valuable insights
into the interaction, as reported below.
First, the KD values are highly comparable for the two GST-
fused CD98 sequences (2 and 3 in Figure 7A), going from the
almost full-length M102-A630 protein to the short V304-H414 re-
gion, which unambiguously identifies the V304-H414 sequenceChemistry & Biology 22, 217as the interacting one. This region, which is part of the extracel-
lular domain (see Figure 7A), is highly conserved; in fact, no var-
iants have been described so far within this segment. Notably,
the same region was shown by SPR to interact with proteins
from enteropathogenic E. coli (EPEC) and Citrobacter rodentium
(Shames et al., 2010; Charania et al., 2013).
Sequences 1 and 2 reported in Figure 7A, differing in tags and
glycosylation, produce almost comparable SPR data, which
differ by one order ofmagnitude in the strength of binding. There-
fore, the abundant glycosylation in the human protein and the
GST tag only slightly affect CD98 binding. Two of the four puta-
tive N-glycosylation sites, N365 and N381, are located in the in-
teracting region on helical regions exposed to solvent, thereby
leaving free access to the plasma membrane surface. Finally,
the fully reduced and oxidized forms of hBD3 bind CD98 with
comparable affinity, but with different kinetics. This behavior
can be ascribed to the different 3D structure of the two forms.
DISCUSSION
While the extracellular activity of hBDs is reasonably well under-
stood in terms of direct (e.g. pore formation in bacterial mem-
branes) or indirect (e.g. chemotactic) antimicrobial activity, less–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 221
Figure 5. Competition Binding Assay of
CD98 Versus Labeled and Unlabeled hBD3
(A) Titration curve. A549 cells were incubated with
Biotin-2X-hBD3 (1.25, 2.5, 5, and 10 mM) for 20min
at 4C. hBD3 was revealed by streptavidin-Cy3.
Fluorescence intensity wasmeasured by analyzing
confocal images. Data represent means ± SD of
three separate experiments inwhich each replicate
reflects the fluorescence intensity from 25 cells/
area.
(B) Competition assay. A549 cells were incubated
with Biotin-2X-hBD3 (3 mM) for 20 min at 4C
(pulse), washed then incubated with hBD3
(3, 15 mM) and labeled with streptavidin-Cy3
(panels b, c). Conversely, the cells were incubated
with unlabeled hBD3 (3, 15 mM) for 20 min at 4C
(pulse), washed then incubated with Biotin-2X-
hBD3 (3 mM) and labeled with streptavidin-Cy3
(panels d, e). Scale bars, 10 mm. Images represent
single 1-mm-thick optical slices.is known about the intracellular role of these molecules. In the
case of hBD3, we and others (Scudiero et al., 2013; Beaumont
et al., 2012) previously reported that hBD3 is internalized in
mammalian cells via an active endocytic mechanism. Moreover,
a recent study devoted to the so-called NSHPs (Cronican et al.,
2011), which are able to penetrate mammalian cells even more222 Chemistry & Biology 22, 217–228, February 19, 2015 ª2015 Elsevier Ltd All rights reservefficiently than the classic cell-pene-
trating peptides (Cronican et al., 2011;
Thompson et al., 2012), showed that
hBD3 has the highest charge/molecular
mass ratio among NSHPs, and hBD3
fused to the mCherry fluorophore is able
to penetrate HeLa, 3T3, and BSR cells
(Cronican et al., 2011). However, little is
known about hBD3 internalization in
epithelial cells, which is the natural site
of action of themolecule, and importantly,
whether internalization is assisted by
interaction with cell surface molecules.
Using a proteomic approach, we have
identified a number of potential interac-
tions between hBD3 and cell surface re-
ceptors in the human epithelial cell line
A549. In particular, we have clarified the
interaction of hBD3 with CD98, a type II
transmembrane protein involved in
L-type amino acid transport, in integrin-
mediated cell adhesion, in inflammation
(Kenworthy and Edidin, 1999), and in the
immune response (Miranda et al., 2003).
CD98 is involved in the innate host
response to intestinal infection by enteric
bacterial pathogens (Quin˜ones-Mateu
et al., 2003). Its overexpression has
been associated with increased expres-
sion of proinflammatory markers, with
decreased expression of anti-inflamma-
tory markers, and with increased attach-ment of EPEC and C. rodentium in mouse colon (Feng et al.,
2006). The exposure of CD98 to the cellular lumen enables the
enteropathogenic bacteria to directly access CD98, resulting in
attachment and bacterially induced inflammation. In addition,
CD98 is highly expressed in several tumors, including lung
and breast, and its overexpression is associated with a poored
Table 1. Kinetic and Equilibrium Constants for the CD98-hBD3 Interaction based on SPR Data




3/s) KD (3107 M)
GST-CD98-hBD3b 4.27 ± 0.03 1.34 ± 0.02 5.73 ± 0.05 0.944 ± 0.004 4.43 ± 0.05
GST-CD98-hBD3c 8.51 ± 0.05 2.10 ± 0.03 9.03 ± 0.06 1.930 ± 0.03 4.35 ± 0.06
GST-CD98-hBD3oxb 19.6 ± 0.09 13.05 ± 0.03 4.04 ± 0.06 0.682 ± 0.004 9.60 ± 0.09
CD98-6His-hBD3b 2.53 ± 0.05 1.79 ± 0.06 6.48 ± 0.02 1.865 ± 0.03 15.84 ± 0.06
CD98-6His-hBD3c 4.26 ± 0.06 2.25 ± 0.07 7.24 ± 0.05 2.163 ± 0.04 12.13 ± 0.07
CD98-6His-hBD3oxb 31.24 ± 0.05 40.79 ± 0.02 2.49 ± 0.09 0.456 ± 0.004 20.22 ± 0.09
GST-CD98cut-hBD3b 4.65 ± 0.07 1.26 ± 0.03 5.44 ± 0.06 0.907 ± 0.007 3.86 ± 0.07
GST-CD98cut-hBD3oxb 26.20 ± 0.02 8.88 ± 0.04 4.23 ± 0.08 0.604 ± 0.003 4.23 ± 0.08
hBD3-GST-CD98c 6.23 ± 0.08 1.28 ± 0.06 5.78 ± 0.07 1.500 ± 0.04 3.99 ± 0.08
hBD3-GST-CD98cutc 5.97 ± 0.09 0.627 ± 0.007 8.58 ± 0.08 0.969 ± 0.006 1.07 ± 0.09
aThe first immobilized compound.
bCM4 sensor chip.
cCM5 sensor chip.prognosis (Feng et al., 2006; Shames et al., 2010; Charania et al.,
2013). It has been suggested that promotion of tumorigenesis is
mediated by the interaction of CD98 with b1-integrins (Cantor
and Ginsberg, 2012; Furuya et al., 2012; Kaira et al., 2011). Since
downregulation of CD98 promotes cell death via apoptosis
(Bulus et al., 2012), the protein has been proposed as a thera-
peutic target (Santiago-Go´mez et al., 2013).
The affinity of hBD3 toward CD98 is within micromolar range.
The ectodomain of CD98 consists of two domains: an N-terminal
globular domain adopts a triosephosphate isomerase (TIM) bar-
rel fold (residuesW218–K532) and a C-terminal domain presents
a b-sandwich-like topology (residues D540–A630) (Figure 7B).
We unambiguously mapped the hBD3-interacting region to
CD98 residues V304–H414, i.e. to the region of the protein that
interacts with the proteins of EPEC and C. rodentium (Shames
et al., 2010; Charania et al., 2013). This region, which corre-
sponds to almost half the b barrel, is built of four b strands
belonging to the barrel and three amphipathic a helices sur-
rounding the barrel. In such a type of fold, a ligand binding site
often lies in a cavity at the top of the barrel, and the loops con-
necting the C terminus of the b strands to the adjacent a helices
provide the key ligand binding residues. In the CD98 region that
interacts with the highly charged hBD3, the loops contain a large
number of negatively charged residues (see Figure 7C). We pro-
pose that this complementary charge interaction is the structural
determinant for CD98-hBD3 recognition, as observed for the
electrostatic interaction of hBD3 with the melanocortin and che-
mokine receptors (Nix et al., 2013; Esseghir et al., 2006).
The affinity of hBD3 toward CD98 depends little on the defen-
sin oxidation state, as does the antimicrobial activity of themole-
cule (Scudiero et al., 2010, 2013). However, our kinetic data,
obtained by SPR, revealed some differences, particularly in the
association phase. This is due to the distinct 3D structure of
the two hBD3 states (see Text S1). Although kinetic parameters
are different, the resulting affinity of the two hBD3 forms toward
CD98 is comparable (Table 1). The formation of the complex
between hBD3 and CD98 does not rule out the occurrence of
multipartner complexes.
To verify the physiological relevance of the proteomic and
in vitro data, we first evaluated the colocalization of CD98 with
hBD3, and found extensive colocalization on the basolateralChemistry & Biology 22, 217domain of epithelial cells (Figure 4A). This result is consistent
with studies reporting CD98 in the basolateral domain of epithe-
lial cells (Mburu et al., 2011; Kaira et al., 2011). We also demon-
strated, by FRET, direct binding of CD98 and hBD3 in cells fixed
and coimmunostained with CD98 and biotin-hBD3 (Figure 4B).
Furthermore, the specificity of CD98/BD3 binding is strongly
supported by the results of the competition binding assay (Fig-
ure 5), which indicates that once hBD3 binds to the cell surface,
this binding is specific and occurs with an affinity consistent with
the KD obtained in SPR experiments. Having established the
hBD3-CD98 interaction in vitro and in cells, we then asked if
CD98 could play a functional role in the antibacterial activity of
hBD3. Our SPR data suggest that hBD3 could act through
competition withmicrobial ligands for the region of CD98 that en-
ables bacterial invasion (Shames et al., 2010). In addition, we hy-
pothesized that hBD3 might downregulate the expression of
CD98, which would have a further inhibitory effect on bacterial
invasion (Feng et al., 2006). This mechanism would be similar
to that identified for the HIV coreceptor CXCR4 in human oral
epithelial and immunocompetent cells, the internalization and
downregulation of which are modulated by both hBD2 and
hBD3 (Esseghir et al., 2006; Cai et al., 2005).
As shown in Figure S5, treatment of A549 cells with hBD3
dramatically reduced the expression of CD98 24 hr post treat-
ment. Our analysis of hBD3 internalization showed that, after
this interaction, hBD3 is internalized bymeans of recycling endo-
somes (Figures 2A, 2B, and 6) and accumulates with transferrin
(Figure 2B), suggesting that hBD3 avoids lysosome degradation
and is sorted back to the cell surface. This would enable the pep-
tide to downregulate CD98 to reduce invasion and to exert direct
antibacterial activity at the surface epithelium.
In conclusion, our results suggest an additional mechanism
whereby hBD3 exerts antibacterial activity, namely, a mecha-
nism involving its accumulation on mucosal surfaces. Moreover,
since CD98 is overexpressed in several tumors and is associated
with a poor prognosis (Cantor and Ginsberg, 2012; Furuya et al.,
2012), one could speculate that hBD3 plays a role also in the
innate immune surveillance of malignancy. For both activities,
the moderate (mM) affinity of the hBD3-CD98 interaction would
ensure that binding and the ensuing downregulation are maxi-
mized in CD98-overexpressing cells, thereby leaving the cells–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 223
Figure 6. Biotin-2X-hBD3 and CD98 Internalization
(A) A549 cells were grown on filters for 72 hr, incubated with the peptide
(10 mM) for 20 min at 4C (pulse), then washed and immunostained with CD98.
Biotin-2X-hBD3 colocalized with CD98 at different chase times: 0 min, 5 min,
15 min, 30 min. Scale bars, 10 mm. Images represent single 1-mm-thick optical
slices. Biotin-2X-hBD3 is red and CD98 green; colocalizing regions appear
orange-yellow in the overlay image (see arrows). Three independent experi-
ments were performed, and images were acquired from at least 100 cells per
experiment.
(B) Biotin-2X-hBD3 does not bind the plasmamembrane and is not internalized
into A549 cells when CD98 is silenced. CD98 was silenced using a specific
siRNA for 72 hr in A549 cells. Then, cells were incubated with the peptide
(10 mM) for 20 min at 4C (pulse), then washed and immunostained with CD98.
A549 cells were incubated with the peptide (10 mM) for 20 min at 4C (pulse),
washed, incubated at 37C and labeled with CD98. Biotin-2X-hBD3 is
red, CD98 is green. Three independent experiments were performed, and
images were acquired from at least 100 cells per experiment. See also Figures
S4 and S5.
Figure 7. Characterization of CD98-hBD3 Interaction
(A) The selected CD98 sequencing regions studied as interactors of hBD3
peptide by SPR.
(B) Schematic representation of the whole CD98 heterodimer. (Top) Ribbon
representation of the CD98 heavy domain from the Protein Data Bank file
2DH2. In this view, the TIM barrel fold is clearly visible from the top of the b
barrel with surrounding a helices. The region (V304–H414) interacting with
hBD3 is drawn in red. The preceding and following protein regions are colored
in yellow and green, respectively. (Bottom) Cartoon of the transmembrane light
chain helices (blue) linked by a disulfide bond involving C210 of the heavy
domain.
(C) A close-up view of the interacting region consisting of four b strands
(belonging to the barrel) and three a helices. Numerous negative residues
(labeled) lie on the loops connecting the strands to the helices, at the top of the
barrel. The blue semicircle traces the barrel closure. See also Figure S6.with normal CD98 expression unperturbed. Moreover, the iden-
tification of the specific region of interaction between hBD3 and
CD98 may be exploited to design higher-affinity hBD3 variants
for possible therapeutic applications. The novel findings of this
study pave the way for further development toward a therapeutic
approach.224 Chemistry & Biology 22, 217–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved
SIGNIFICANCE
hBD3 exerts antimicrobial activity at epithelial surfaces
through a variety of mechanisms. With its highly positively
charged amphipathic structure stabilized by a triple-disul-
fide bond, it is able to severely damage the bacterial mem-
branes, while being readily internalized into host cells.
Here, we show that internalization of hBD3 in lung A549
cells is assisted by CD98, a multifunctional transmembrane
protein. The binding site of hBD3 is located in a CD98 nega-
tively charged pocket, which coincides with the region
bound by the intestinal bacteria EPEC and C. rodentium
during invasion of colonic tissue. Notably, hBD3 binding
also downregulates CD98 expression. Our study reveals a
novel antimicrobial mechanism of hBD3, i.e. competitive
binding for a bacterial invasion receptor driven by electro-
static complementarity. This mechanism may apply to
other defensin-receptor partners yet to be discovered.
EXPERIMENTAL PROCEDURES
Biotinylated Peptide Synthesis
The reduced form of hBD3 was synthesized using standard 9-fluorenylme-
thoxycarbonyl (Fmoc) solid-phase methods, as previously reported (Scudiero
et al., 2010, 2013), and purified by preparative reverse-phase-high pressure
liquid chromatography (RP-HPLC) on a C18 column (2 x 250 mm, 5 mm,
Phenomenex), using as solvent system H2O/0.1% TFA (A) and CH3CN/
0.1% TFA (B), and a linear gradient 5%–50% B over 17 min, flow rate
20 ml/min. Analytical RP-HPLC used a Phenomenex C18 column (4.6 x
250 mm, 5 mm). The identity of the purified peptides was confirmed by
electron spray ionization liquid chromatography-mass spectrometry (ESI
LC-MS) using a Thermo Electron MSQ Surveyor. Biotin labeling of the
reduced hBD3 was performed on the resin-bound peptide. Briefly, 70 mg
of resin-bound peptide (25 mmol) was treated with piperidine in dimethylfor-
mamide to remove the Fmoc group and then reacted for 24 hr with 2X-AH-
biotin-N-hydroxysuccinimide ester (Biotin-2X, Sigma-Aldrich) in the presence
of 4-dimethylaminopyridine (Sigma-Aldrich). Cleavage conditions were the
same as for the unlabeled peptide. Compound identity was confirmed
by LC/MS. The oxidized form of HBD3 was purchased from Peptides
International.
Antibacterial Activity Assay
For the colony-forming unit (CFU) assays of antibacterial activity against E. coli
(ATCC 25922), the strain was grown under aerobic conditions in tryptic soy
broth (Difco Laboratories) at 37C and incubated with the peptide for 2 hr at
37C. Two peptide concentrations, 2.5 mM and 12.5 mM, were used. For the
salt dependence assay, 0.0, 50, 100, and 200 mM NaCl were included in the
incubation buffer, as reported elsewhere (Scudiero et al., 2013). Each assay
was performed in triplicate. The minimum inhibitory concentration of the three
peptides was determined with the modified version of the broth microdilution
assay of the Clinical and Laboratory Standards Institute, using a final inoculum
concentration of 105 cfu/ml. The peptide concentrations were 100, 50, 25,
12.5, 6.25, 3.12, and 1.56 mM.
Cell Culture
A549 cells were obtained from the Bank of Human and Animal Continuous Cell
Lines (CEINGE-Biotecnologie Avanzate). A549 were grown in 90% DMEM
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Lonza)
and 1% L-glutamine (Sigma-Aldrich). The cells were grown as a monolayer
in a flask at 37C in 5% CO2.
A549 Cell Transfection by CD98 siRNA
The CD98-specific and scrambled control siRNAs were obtained from
Novus Biologicals. Transfection of A549 cells was performed using
LipofectAMINE2000 (Invitrogen) according to the manufacturer’s instructions.Chemistry & Biology 22, 217Formaldehyde Crosslinking
A549 cells (2 x 106) were plated on 100 mm dishes and cultured in DMEM con-
taining 10% FBS for 48 hr. Cells were washed three times with PBS and then
incubated for 20 min at 4C with Biotin-hBD3 (10 mM in H2O) or with 10 mM
Biotin-2X in H2O as control. Biotin-hBD3 was crosslinked to putative interact-
ing proteins using formaldehyde, which efficiently produces reversible protein-
protein crosslinks in vivo (Sutherland et al., 2008; Klockenbusch and Kast,
2010). Cells were treated with a 1.0% w/v solution of paraformaldehyde in
PBS at room temperature. Formaldehyde crosslinking was allowed to proceed
for 10min at room temperature, then the reaction was quenched by addition of
1.25 M glycine to a final concentration of 125 mM, for 5 min at room temper-
ature. Cells were harvested, washed twice with PBS, and then treated with
the Subcellular Protein Fractionation Kit (Pierce Biotechnology) to isolate
plasma, mitochondria, and ER/Golgi membrane components, excluding nu-
clear membranes. Cell lysates were centrifuged for 15 min at 14,000 rpm to
precipitate cell debris. Supernatants were collected and protein levels quanti-
fied using a BCA protein assay kit (Pierce Biotechnology).
Affinity Chromatography
To isolate peptide-protein complexes, protein extracts were incubated with
MagStrep type 2HC magnetic beads (IBA) using 40 ml of extract/mg of beads,
containing IP buffer (Tris-HCl 50mM [pH 7.5], NaCl 150mM, NaF 1mM, PMSF
1 mM, Nonidet P-40 1%, 1 mM EDTA, 1 mM sodium orthovanadate) and Pro-
tease inhibitor cocktail (Complete mini EDTA-free, Roche Applied Science), for
30min at 4Con a rocker platform. Supernatants were then separated from the
beads using a magnetic separator. After extensive washing of the pellet beads
with IP buffer, the resulting peptide-protein complexes were decrosslinked
and eluted from the beads with 23 electrophoresis sample buffer at 90C
for 10 min. The protein mixture was then resolved by electrophoresis on
10% SDS-PAGE and stained with Coomassie brilliant blue (Pierce Biotech-
nology). Each lane of the gel was cut into slices and processed for LC-MS/
MS analysis.
Western Blotting
ForWestern blot analysis, proteinswere resolved by 10%SDS-PAGE and then
transferred onto nitrocellulose membranes (GE Healthcare) by Mini Trans-Blot
electrophoretic transfer (Bio-Rad). Membranes were blocked using 5% nonfat
milk in PBS (pH 7.5) for 2 hr and then immunoblotted with antibodies against
histone H3 (1:1000), EGFR (1:1000), GAPDH (1:2000), CD98 (1: 250) (Santa
Cruz Biotechnology), anti-H3 (Abcam), and Hrp-conjugated streptavidin (Cell
Signaling Technology). The Western blot images obtained were scanned by
PDquest 7.1 software (Bio-Rad). The protein band images on X-ray films
were acquired with the Chemidoc XRS system (Bio-Rad). GAPDH was used
as loading control, since it is equally expressed in all the cell lines considered.
We used the Quantity One 4.5 tool (Bio-Rad) for densitometric measurements.
LC-MS/MS and Data Analysis
Gel slices were placed in Eppendorf tubes andwashedwith 50mMammonium
bicarbonate for 10min, and destained twice with 50mM ammonium bicarbon-
ate followed by acetonitrile for 15 min. The gel slices were dehydrated by incu-
bation with acetonitrile for 15 min and vacuum dried in a SpeedVac. The dried
gel slices were treated with proteomics grade trypsin (Sigma-Aldrich) at 37C
overnight. The sampleswere briefly spun and supernatants were transferred to
clean dry Eppendorf tubes. Peptides were further extracted from the gel once
with 0.1% trifluoroacetic acid in 50% acetonitrile for 10min followed by aceto-
nitrile for 20 min at 37C. Pooled supernatants were dried in a SpeedVac.
Before LC-MS/MS analysis, the samples were reconstituted with 10 ml of
0.2% formic acid. LC-MS/MS analysis was performed on an LC/MSD Trap
XCT Ultra system equipped with a 1100 HPLC-Chip Cube interface (Agilent
Technologies). The peptide sample was concentrated and washed on a
40-nl enrichment column (Agilent Technologies chip), using as eluent 0.1%
formic acid at 4 ml/min, then fractionated on a C18 reverse-phase capillary col-
umn (75 mm x 43 mm) using a flow rate of 200 nl/min and a linear gradient of
5%–60% acetonitrile in 2% formic acid. Subsequently, we analyzed the pep-
tides using data-dependent acquisition of one MS scan (mass range from 400
to 2000 m/z) followed by MS/MS scans of the three most abundant ions. To
obtain a more detailed survey of the peptides, we carried out dynamic exclu-
sion using a procedure of automatic recognition and temporary exclusion–228, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 225
(2 min) of ions from which definitive mass spectral data had previously been
acquired.
Data were analyzed with MASCOT software (version 2.4) Peptide Mass
Fingerprinting search program (http://www.matrixscience.com), selecting
the NCBInr aug2010 database (11592891 sequences, http://www.ncbi.nlm.
nih.gov), and the following six parameters: specificity of the proteolytic
enzyme used for hydrolysis (trypsin) up to 1 missed cleavage; Cys such as
S-carbamidomethyl Cys; unmodified N- and C-terminal ends; unmodified
and oxidized methionines; putative Gln-induced pyroGlu formation; a precur-
sor peptide maximum mass tolerance of 400 ppm and a maximum fragment
mass tolerance of 0.6 Da. Using the probability-based Mowse score, the ion
score is –10 x log(P), P being the probability that an eventual match is a
random occurrence. All MS/MS spectra with a MASCOT score >41 (p %
0.05) had a good signal to noise ratio, so the interpretation of the data
was unambiguous. MS/MS spectra of peptides that had a MASCOT
score <41 were inspected manually and included in the statistics only in
the presence of at least four continuous y or b ions. We also used the BLAST
program (http://ncbi.nlm.nih.gov/blast) and the NCBI database to search for
the peptide sequence. Peptides with an ambiguous identification were
removed from the list. Specifically, the candidate protein was deleted from
the list when it matched other proteins. Protein species identified by a single
peptide were examined further. We manually reconstructed the peptide
sequence stretch, and analyzed it and the precursor ion mass with the
MASCOT software set in the sequence query mode. Proteins found also in
the control samples were considered nonspecific and excluded from the
list of identified proteins.
Confocal Microscopy
A549 cells were seeded at 25% confluence in WillCo glass bottom dishes
(WillCo Wells) or Transwell clear Constar filters (3460). For plasma membrane
localization, cells were incubated with 10 mM of Biotin-2X-hBD3 for 20 min at
4C (pulse); hBD3-containing medium was then replaced with fresh growth
medium and cells were incubated with streptavidin-Cy3, washed and stained
with a rabbit (BD-Bioscience) primary antibody against a marker of the baso-
lateral cell membrane (E-cadherin) followed by an Alexafluor 488-conjugated
secondary antibody. The samples were fixed with 3% paraformaldehyde
(Sigma-Aldrich) and analyzed by confocal laser scanning microscopy. To
ensure that neither biotin nor streptavidin interferes with fluorescent signals,
we used cells treated with biotin and stained with streptavidin-Cy3 as controls;
no fluorescence signal was detected (data not shown).
Internalization Assay by Fluorescence Microscopy
A549 cells were grown on glass bottom dishes for 24 hr, washedwith PBS, and
processed for the endocytic assay. Briefly, cells were incubated with both
10 mM of Biotin-2X-hBD3 and transferrin-Alexa 488 conjugated for 20 min at
4C (pulse). Then the cells were warmed at 37C for the indicated times (chase)
to allow hBD3 and transferrin internalization, and were fixed with paraformal-
dehyde 3%, permeabilized with TX-100 0.1% in PBS/BSA 1% for 10 min and
incubated with streptavidin-Cy3 for 20 min to label hBD3.
FRET
A549 cells seeded in WillCo glass bottom dishes (35/22 mm) were grown in
DMEM supplemented with 10% fetal calf serum and 1% L-glutamine. FRET
experiments were performed 24 hr post plating. FRET was measured with
the acceptor photobleaching technique (Kenworthy and Edidin, 1999) where,
upon irreversible photobleaching, the donor fluorescence increase was re-
corded. Cells were incubated with 10 mMBiotin-2X-hBD3 for 20min at 4C fol-
lowed by Cy5-conjugated streptavidin to specifically label Biotin-2X -hBD3.
After fixation, cells were immunostained with specific goat primary anti-
CD98 antibody (Santa Cruz Biotechnology) and revealed by secondary anti-
goat Cy3-conjugated antibody. Acceptor photobleaching experiments were
performed with the Leica TCS SMD SP5 confocal microscope with an oil
immersion 63x (numerical aperture 1.4) objective lens. Excitation at 561 and
633 nm was used for Cy3 and Cy5, respectively. For Cy5 bleaching, the
633 nmHe-Ne laser light with 100%output power was used and pinhole diam-
eters were set to 1.0 mm optical slices. FRET measurements were obtained
with the LAS AF software (Leica) after photobleaching of a selected squared
region of interest. We calculated FRET efficiency using the following equation:226 Chemistry & Biology 22, 217–228, February 19, 2015 ª2015 ElseE = (fluorescence intensity of Cy3 after bleaching – fluorescence intensity of
Cy3 before bleaching)/fluorescence intensity of Cy3 after bleaching.
As control: (1) wemeasured FRET on cells immunostained with primary anti-
CD98 followed by Cy3-conjugated secondary antibody alone to ensure that
photobleaching per se does not affect the fluorescence of the donor and
that photoconversion does not occur during the photobleaching analysis;
and (2) as indicated in Figure 4, we stained cells with primary anti-CD98 and
secondary-Cy3 conjugated antibody followed by labeling with streptavidin-
Cy5 without Biotin-2X-hBD3 incubation. We calculated the background raised
by the photobleaching per se by bleaching Cy5 in cells negative for this fluo-
rophore. The background value was subtracted from all samples. All the
experiments were done in triplicate and data are means ± SD of three indepen-
dent experiments.
Competition Binding Assay
To select the peptide concentration at which to perform the competition
assay, different concentrations of labeled Biotin-2X-hBD3 were incubated
with the cells to obtain a titration curve. Confocal images of cells incubated
with different concentrations of Biotin-2X-hBD3 were evaluated for fluores-
cence intensity with the LAS AF software considering the signal deriving
from the 10 mM hBD3 incubation as 100%. Data were normalized by
analyzing the same area for all samples. A concentration of 3 mM was chosen
by extrapolation of the linear trend for the competition assay. A549 cells were
grown in normal growth medium on WillCo glass bottom dishes. On the day
of the analysis, the medium was removed and cells were washed twice with
cold PBS and the required concentration of unlabeled (hBD3) or labeled
(Biotin-2X-hBD3) compound was added. Briefly, the cells were first incu-
bated with labeled Biotin-2X-hBD3 for 20 min at 4C, washed twice and
increasing amounts of unlabeled hBD3 were added for a further 20 min on
ice. Conversely, the cells were first incubated with unlabeled hBD3 for
20 min at 4C, washed and then stained with labeled Biotin-2X-hBD3.
hBD3 was revealed by streptavidin Cy3-conjugated. In both cases, CD98
was revealed with the same procedure described elsewhere (Stoddart
et al., 2012).
SPR
SPR experiments were performed using a Biacore T200 system (GE Health-
care) at 25C. Binding assays were carried out between various CD98 se-
quences and both reduced and oxidized hBD3. Hereafter residue numbering
is referred to CD98 isoform-1.
First, the protein sequences GST-CD98 (102–630) (Novus Biologicals),
CD98-6His (206–630) (Novoprotein), and the truncated GST-CD98 (304–414)
(Novus Biologicals) were immobilized on a CM4 and/or a CM5 sensor chip
(research grade) by the standard amine coupling procedure, using HBS-EP
buffer (HEPES 10 mM, NaCl 150 mM, EDTA 3 mM, Surfactant P20 0.005%
[pH 7.4]), as running buffer. The CD98 forms were immobilized through activa-
tion of the sensor chip with 60 ml of N-hydroxysuccinimide and N-ethyl-N-(di-
methylaminopropyl)-carbodiimide at 10 ml/min, followed by a 30 ml injection of
CD98 forms diluted in 10 mM sodium acetate buffer (pH 4.0). Unreacted acti-
vated groups were blocked by a 60 ml injection of 1 M ethanolamine at
10 ml/min. The final CD98 immobilized levels were typically between 1,500
and 5,000 RU, corresponding to a protein concentration of 15 O 50 mg/ml
on the surface layer. Subsequently, both reduced and oxidized hBD3 were in-
jected as analyte at various concentrations (from 100 nM to 100 mM), and using
the same HBS-EP buffer as running buffer. All binding assays were performed
under various conditions: (1) a contact time of 60 s and 120 s and a dissociation
time of 600 s and 1000 s to evaluate the best kinetic model; (2) a flow rate of 30
and 60 ml/min to evaluate the contribution of mass transport.
Second, hBD3 was immobilized on a CM5 sensor chip (research grade) by
the standard amine coupling procedure, using HBS-EP buffer as running
buffer, under the same conditions as described above. After the sensor chip
activation as before, 30 ml of hBD3 diluted in 10 mM sodium acetate buffer
(pH 5.5) was injected and finally unreacted activated groups were blocked
as described above. Then, the two GST-fused CD98 protein sequences
were injected as analytes at various concentrations (from 20 nM to 20 mM),
and using HBS-EP buffer as running buffer. As control, GST was immobilized
on a CM5 sensor chip and hBD3 was allowed to flow, following the procedure
described above.vier Ltd All rights reserved
The SPR sensorgrams for each CD98-hBD3 interaction were analyzed by
curve fitting using the Biacore T200 Evaluation software. Dose-response
curves were plotted using the SPR sensorgrams and the corresponding fit.
Various reaction models were used to perform a complete kinetic analysis of
the sensorgrams, and the best fitting was considered in such a way that the
c2 value, representing the statistical closeness of curve fitting, became the
lowest. The two-state reaction model (including a conformational change)
was chosen, which is described as
A +B%AB%AB
where A is the immobilized CD98 form, B is hBD3, AB represents the protein-
hBD3 complex and AB* represents the stable complex after the conforma-
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